Oklo Inc. (NYSE: OKLO) has received a major regulatory boost after the U.S. Department of Energy approved the Documented Safety Analysis for its Groves Isotope Test Reactor in Texas.
The approval was granted under the DOE’s Reactor Pilot Program and represents an important milestone in establishing the facility’s final safety basis.
The latest clearance follows an earlier approval of the Preliminary Documented Safety Analysis, with the two together marking significant forward progress for the project.
Together, the dual approvals allow the Groves Isotope Test Reactor to move out of the documentation phase and into the final pre-startup review stage.
Successfully clearing the startup review will enable Oklo to receive and load nuclear fuel and proceed with startup testing at the Texas facility.
Oklo has set an ambitious internal target of achieving first criticality at the Groves facility during July 2026, signaling confidence in the project’s near-term timeline.
The Groves facility is central to Oklo’s isotope business strategy, which is designed to support a robust domestic supply chain for critical isotopes used across multiple sectors.
The company sees the facility positioning it as a key supplier of isotopes serving scientific research, space exploration, and national security applications.
Oklo describes itself as an advanced nuclear technology company focused on developing next-generation, fast-fission power plants intended to deliver clean, reliable, and affordable energy.
Hedge fund sentiment around the stock has been notably positive, with analysts identifying Oklo as one of the top mid-cap stocks to hold over a multi-decade investment horizon.
The Groves approvals arrive at a time when domestic nuclear energy and isotope production are drawing renewed attention from both government agencies and private investors.
With regulatory momentum building and first criticality potentially weeks away, Oklo’s near-term operational milestones could serve as significant catalysts for the stock going forward.
